Steroid induced central serous retinopathy following follicular unit extraction in androgenic alopecia
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20161587Keywords:
Hair transplantation surgery, Optical coherence tomography, Central serous retinopathy, Prednisolone, Hamilton anxiety rating scaleAbstract
Dermatologists for various conditions and procedures commonly use corticosteroids worldwide. The development of central serous retinopathy is a lesser known complication occurring in <10% of the cases with steroid use. This case report highlights the development of central serous retinopathy after prescribing low dose of prednisolone 20 mg per day for androgenic alopecia during post-surgical follicular unit extraction (FUE) surgery follow-up that recovered spontaneously after gradual withdrawal of steroids. Therefore, awareness is required for its early detection and management as it has a potential of causing irreversible visual impairment.
References
Hardwig PW, Silva AO, Pulido JS. Forgotten exogenous corticosteroid as a cause of central serous chorioretinopathy. Clin Ophthalmol. 2008;2:199-201.
Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol. 2010;22:166-73.
Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR. Central serous chorioretinopathy in African-Americans. J Natl Med Assoc. 2003;95(7):553-9.
Guyer DR, Gragoudas ES, Spaide RF. Central serous chorioretinopathy. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology, 2nd ed. Philadelphia: WB Saunders Company; 2000:3:1974-1982.
Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN Elliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmolgy. 1997;104:1653-60.
Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging. 2004;35(2):165-7.
Acar U, Kucuk B, Agin A, Koc M, Sobaci G. Case report of tadalafil-induced central serous chorioretinopathy. J Clin Exp Ophthalmol. 2014;5:357.
Cotticelli L, Borrelli M, D'Alessio AC, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy and Helicobacter pylori. Euro J Opthalmol. 2006;16(2):274-8.
Moon SJ, Meiler WF. Retinal complications of bone marrow and solid organ transplantation. Curr Opin Ophthalmol. 2003;14(6):433-42.
Kian-Ersi F, Taheri S, Akhlaghi MR. Ocular disorders in renal transplant patients. Saudi J Kidney Dis. Transpl. 2008;19(5):751-5.
Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye Lond. 2010;24:1743-56.
Jenkins CD, Zyzanski SJ, Rosenman RH. Progress toward validation of computer-scored test for the type A coronary-prone behavior pattern. Psychosomatic Medicine. 1971;33:193-202.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psycho. 1959;32:50-5.
Clinical global impression. ECDEU assessment manual for psychopharamacology. Guy W, ed, Rockville, MD: US Department of Health, Education and Welfare, DHEW Publication No. (ADM); 1976:76-338.
Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN Elliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmolgy. 1997;104:1653-60.
Mondal LK, Sarkar K, Datta H, Chatterjee PR. Acute bilateral central serous chorioretinopathy following intra-articular injection of corticosteroids. Indian J Ophthamol. 2005;53:132-4.
Karadimus P, Kapitanjos A, Bouzas EA. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders. Arch Ophthalmol. 2004;122:784-6.
Zamir E. Central serous chorioretinopathy associated with adrenocorticotrophic hormone therapy. A case report and hypothesis. Arch Clin Exp Ophthalmol. 1997;235:339-44.
Wakakura M, Song E, Ishikawa S. Corticosteroid-induced central serous chorioretinopathy. Jpn J Opthalmol. 1997;41:180-5.
Caccavale A, Romanazzi F, Imparto M, Neagri A, Marro A, Ferentini F. Low dose aspirin as treatment of central serous chorioretinopathy. Clin Ophthmol. 2014;4:899-903.
Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor-1 in central serous chorioretinopathy. Am J Ophthmol. 1999;127(4):477-8.
WHO-UMC org. The uppsala monitoring centre. Available from: http://www.who-umc.org/. Accessed 19 February 2016.
Schumock GT, Thomton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.
American academy of ophthalmology. Basic and clinical sciences course. Retina and vitreous USA. San Francisco. 2008-2009;4:55-9.
Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752-63.
Lim JW, Ryu SJ, Shin MJ. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol. 2010;24(3):155-8.
Golshahi A, Klingmuller D, Holtz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol. 2010;88(5):576-81.
